{"id":16619,"date":"2016-12-07T17:45:10","date_gmt":"2016-12-07T16:45:10","guid":{"rendered":"http:\/\/alcyon:7777\/transgene170914\/?p=16619&#038;lang=fr"},"modified":"2021-11-20T11:04:21","modified_gmt":"2021-11-20T10:04:21","slug":"uc-davis-realisera-un-essai-clinique-de-phase-2-evaluant-tg4010-en-combinaison-avec-opdivo-nivolumab-en-2eme-ligne-de-traitement-du-cancer-du-poumon-non-a-petites-cellules-nsclc-au-stade-ava","status":"publish","type":"post","link":"https:\/\/www.transgene.com\/fr\/uc-davis-realisera-un-essai-clinique-de-phase-2-evaluant-tg4010-en-combinaison-avec-opdivo-nivolumab-en-2eme-ligne-de-traitement-du-cancer-du-poumon-non-a-petites-cellules-nsclc-au-stade-ava\/","title":{"rendered":"UC Davis r\u00e9alisera un essai clinique de Phase 2 \u00e9valuant TG4010 en combinaison avec Opdivo\u00ae (nivolumab) en 2\u00e8me ligne de traitement du cancer du poumon non \u00e0 petites cellules (NSCLC) au stade avanc\u00e9 \/ Essai clinique soutenu par Transgene et Bristol-Myers Squibb"},"content":{"rendered":"<p><a href=\"\/wp-content\/uploads\/2016\/12\/161207-Collaboration_UC_Davis_Transgene-BMS_FR.pdf\">UC Davis r\u00e9alisera un essai clinique de Phase 2 \u00e9valuant TG4010 en combinaison avec Opdivo\u00ae (nivolumab) en 2\u00e8me ligne de traitement du cancer du poumon non \u00e0 petites cellules (NSCLC) au stade avanc\u00e9 \/ Essai clinique soutenu par Transgene et Bristol-Myers Squibb<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>UC Davis r\u00e9alisera un essai clinique de Phase 2 \u00e9valuant TG4010 en combinaison avec Opdivo\u00ae (nivolumab) en 2\u00e8me ligne de traitement du cancer du poumon non \u00e0 petites cellules (NSCLC) au stade avanc\u00e9 \/ Essai clinique soutenu par Transgene et Bristol-Myers Squibb<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_coblocks_attr":"","_coblocks_dimensions":"","_coblocks_responsive_height":"","_coblocks_accordion_ie_support":"","_uag_custom_page_level_css":"","footnotes":""},"categories":[129,11,16],"tags":[],"class_list":["post-16619","post","type-post","status-publish","format-standard","hentry","category-129","category-press-release-fr","category-tg4010-fr","entry"],"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"post-thumbnail":false},"uagb_author_info":{"display_name":"alcyon","author_link":"https:\/\/www.transgene.com\/fr\/author\/alcyon\/"},"uagb_comment_info":0,"uagb_excerpt":"UC Davis r\u00e9alisera un essai clinique de Phase 2 \u00e9valuant TG4010 en combinaison avec Opdivo\u00ae (nivolumab) en 2\u00e8me ligne de traitement du cancer du poumon non \u00e0 petites cellules (NSCLC) au stade avanc\u00e9 \/ Essai clinique soutenu par Transgene et Bristol-Myers Squibb","_links":{"self":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/posts\/16619","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/comments?post=16619"}],"version-history":[{"count":0,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/posts\/16619\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/media?parent=16619"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/categories?post=16619"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/tags?post=16619"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}